CODX Stock Rockets As Saudi Facility And Ebola Assay Shift Outlook

Co-Diagnostics Inc. stocks have been trading up by 30.67 percent following upbeat sentiment around its diagnostic technology developments.

Live Update At 10:02:52 EDT: On Tuesday, May 26, 2026 Co-Diagnostics Inc. stock [NASDAQ: CODX] is trending up by 30.67%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CODX has gone from sleepy to explosive on the chart. In early May, Co-Diagnostics stock chopped around the $1.50 area. Then volume and volatility hit. By 2026/05/22, CODX had already jumped from $2.39 to a $5.07 close. On 2026/05/26, it pushed again, trading as high as $7.39 before settling near $6.63. That’s a multi-bagger move in just a couple of weeks, exactly the kind of action momentum traders hunt.

Under the hood, Co-Diagnostics is still a story stock. Revenue last quarter was only about $0.15M, with CODX booking a net loss of roughly $9.14M and negative EPS of -$4.06. Gross margin is positive, but heavy research and development and G&A spending are driving big operating losses. Cash remains a key buffer: CODX reported about $8.23M in cash and a current ratio of 2.3, with limited debt.

More Breaking News

• No Analysis Provided
• No Analysis Provided
• JOBY Stock Climbs As eVTOL Demos And Cash Pile Draw Trader Focus
• No Analysis Provided

For traders, that mix—shrinking revenue, large losses, but cash runway—screams “speculative catalyst play.” CODX is not priced for steady earnings; it’s moving on news, headlines, and the possibility of future diagnostics demand.

Why Traders Are Watching CODX Momentum

The recent CODX breakout is all about catalysts lining up with a low-priced biotech chart. Co-Diagnostics announced that its joint venture, CoMira Diagnostics, has finalized a lease for a 14,400-square-foot, turnkey manufacturing facility in Sudair Industrial City, Saudi Arabia. That takes the Saudi strategy from PowerPoint to pavement. Traders love that shift from concept to execution.

This facility is meant to localize production of the Co-Dx PCR platform, plus diagnostic instruments, lab equipment, and consumables, aimed at Saudi Arabia and the broader MENA region. Tying CODX into Saudi Vision 2030 gives the story a bigger macro hook: local manufacturing, regional health security, and potential access to government-backed programs and tenders. None of that guarantees revenue, but it gives CODX a clear narrative that momentum traders can latch onto.

At the same time, Co-Diagnostics has completed an assay development strategy for the Bundibugyo strain of Ebola after the WHO declared a public health emergency in the DRC and Uganda. This does not mean CODX is suddenly printing money from Ebola tests. It means the company is positioned to rapidly commercialize a PCR-based Ebola Bundibugyo test if demand ramps.

Put these together and you see why CODX is swinging so hard. The stock is trading on future optionality: Saudi production, regional expansion, and an agile infectious disease platform ready to spin up niche tests. For day traders and swing traders who thrive on volatility, CODX is now squarely on the radar.

Conclusion

For active traders, CODX is a textbook example of a catalyst-driven biotech move. Co-Diagnostics has weak near-term financials, but it has fresh story fuel: a Saudi manufacturing footprint via CoMira and a ready-to-go Ebola Bundibugyo assay strategy. The market is not rewarding current profits; it’s reacting to the chance that CODX turns these moves into contracts, volumes, and future revenue streams.

That’s why risk management is everything here. CODX has already run from the $1s into the $6–$7 range in a short window. The intraday tape shows wild swings, with sharp spikes over $7.50 and fast drops back into the $6s. A stock that can double in days can also cut in half just as quickly. Co-Diagnostics trades like a momentum vehicle, not a slow-and-steady compounder.

Traders in the Tim Sykes community know how to approach a name like CODX: plan the trade, respect key levels, and never marry the story. Consistency matters just as much as pattern recognition in this kind of volatile environment. As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.”. As Tim Sykes likes to remind people, “The market doesn’t care about your excuses, only your execution.” Co-Diagnostics gives plenty of story, plenty of volatility, and plenty of opportunity for disciplined traders—strictly for those who understand this is educational and research-oriented analysis, not a signal to buy or sell.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.